|February 14, 2013|
|09:02 EDT||ACTG||Acacia reaches settlement with Mallinckrodt over Exalgo |
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
|March 30, 2015|
|06:09 EDT||ACTG||Acacia Research enters into settlement, patent license agreement with Elavon|
Acacia Research announced that its Credit Card Fraud Control Corporation subsidiary has entered into a settlement and patent license agreement with Elavon. The agreement resolves litigation that was pending in the United States District Court for the Northern District of Texas.
|March 26, 2015|
|06:00 EDT||ACTG||Acacia Research enters into settlement, patent license agreement with Leica|
Subscribe for More Information
|March 20, 2015|
|09:02 EDT||ACTG||Acacia Research management to meet with JPMorgan|
Meeting to be held in Salt Lake City on March 24 hosted by JPMorgan.
|March 17, 2015|
|06:03 EDT||ACTG||Acacia Research subsidiary resolves litigation with Garmin International|
Acacia Research announced that its American Vehicular Sciences subsidiary has entered into a settlement and patent license agreement with Garmin International and Garmin USA. The agreement resolves litigation that was pending in the U.S. District Court for the Eastern District of Texas.